[144] Johnson & Johnson SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Johnson & Johnson (JNJ) reports a proposed sale of 9,570 shares of Common stock through Fidelity Brokerage Services with an aggregate market value of $1,695,805.91, to be sold approximately on 08/29/2025 on the NYSE. The filing lists total shares outstanding as 2,408,338,872.

The filer indicates the shares were acquired via an option (granted 02/13/2017) and the acquisition and payment date is recorded as 08/29/2025 with payment in cash. No other securities were reported sold in the past three months and the form contains the standard certification regarding lack of undisclosed material information.

Insights

Securities Analyst

TL;DR: Routine insider sale notice of 9,570 JNJ shares; transaction size is small relative to outstanding stock.

The filing documents a planned sale via a broker of 9,570 common shares valued at $1.70 million on the filing date, tied to an option originally granted in 2017. This is a Rule 144 notice that enables compliant disposition by an affiliate or insider. The disclosure is procedural and provides the basic mechanics: broker, share count, aggregate market value, acquisition method, and payment in cash. There are no reported related sales in the prior three months in this filing.

Corporate Governance Expert

TL;DR: Filing fulfills regulatory disclosure obligations; includes standard insider representations and signature warnings.

The form contains the required certification that the seller is not aware of any undisclosed material adverse information and references trading-plan provisions. It records the option grant date and the broker used for sale execution. From a governance perspective, the filing appears complete for a Rule 144 notice and does not disclose departures, related-party transactions, or other governance events.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	9570	1695805.91	2408338872	08/29/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/29/2025	Option Granted - 02/13/2017	Issuer			9570	08/29/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for JNJ disclose?

The filing discloses a proposed sale of 9,570 Johnson & Johnson common shares with an aggregate market value of $1,695,805.91, to be sold approximately on 08/29/2025 on the NYSE.

How were the JNJ shares being sold acquired?

The shares were acquired via an option granted on 02/13/2017, with the filing indicating acquisition and payment dated 08/29/2025 and payment in cash.

Which broker is handling the proposed JNJ sale?

The proposed sale lists Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield RI 02917 as the broker of record.

Does the filing report other sales by the seller in the past three months?

No. The section for securities sold during the past three months states Nothing to Report.

What certification does the filer provide on Form 144?

The filer represents by signature that they do not know any material adverse information about the issuer that has not been publicly disclosed and references trading-plan representations where applicable.